Some question if patients want this information, but others say this tool can put risk into context and prompt lifestyle ...

The META-AF trial found fewer recurrences of atrial arrhythmias, a benefit unexplained by weight loss or glycemic control.

The PFA-SHAM trial and MANIFEST-US registry support the efficacy and safety of the increasingly used ablation modality.

EchoPrime was trained on more than 12 million videos; it’s now being tested clinically, with more data expected next year.

There was an increase in the hepatic fat fraction, the long-term consequences of which are unknown, says Robert Rosenson.

The combination therapy improved LVEF, quality of life, clinical outcomes, and more, but implementation questions remain.

The hope is using AI to judge outcomes will ease the high cost and complexity of running big clinical trials, say researchers ...

In TUXEDO-2, ticagrelor failed to meet the bar for noninferiority, with most outcomes hinting at an advantage for prasugrel.

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of ...

Quantifying blood flow instead of relying on angiography alone led to a change in diagnosis for 53% of patients.

The BMJ cited several issues with the PREVENT-TAHA8 study data, concluding that the “results may not be reliable.” ...